Generation of Potent and High-Yield Exosome-Associated AAV (exoAAV) Using Engineered Exosomes
Codiak presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2022 on the Company’s engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene therapy. The data demonstrate that engineering exosomes to encapsulate AAV results in increased yield, resists antibody neutralization in vitro and retains transduction ability.